Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Peritoneal Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Sunitinib 64Nivolumab 42pembrolizumab 36Bevacizumab 32Everolimus 31Sorafenib 25pazopanib 23Axitinib 23cabozantinib 14aldesleukin 13Ipilimumab 13temsirolimus 11Interferon alpha-2 11Cyclophosphamide 10avelumab 9Magnetic Resonance Spectroscopy 9Interleukin-2 9lenvatinib 8atezolizumab 8Radiosurgery 8Gemcitabine 8Immunoglobulin G 7Erlotinib Hydrochloride 7Disulfides 6fludarabine phosphate 5Radiotherapy 5Fluorodeoxyglucose F18 5peginterferon alfa-2b 4Vorinostat 4Tyrosine Kinase Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Renal Cell × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT00085436 2018-06-26

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00913913 2015-12-01

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Dartmouth-Hitchcock Medical Center

Phase 2 Terminated
8 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡